Cwm LLC Has $60,000 Stake in Recursion Pharmaceuticals, Inc. $RXRX

Cwm LLC cut its holdings in Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) by 51.0% during the second quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 11,816 shares of the company’s stock after selling 12,278 shares during the quarter. Cwm LLC’s holdings in Recursion Pharmaceuticals were worth $60,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also recently bought and sold shares of RXRX. AlphaQuest LLC bought a new position in Recursion Pharmaceuticals during the 1st quarter worth approximately $36,000. GAMMA Investing LLC raised its holdings in Recursion Pharmaceuticals by 39.0% in the first quarter. GAMMA Investing LLC now owns 7,224 shares of the company’s stock worth $38,000 after purchasing an additional 2,026 shares during the period. Janney Montgomery Scott LLC acquired a new stake in Recursion Pharmaceuticals in the second quarter worth $51,000. ADG Wealth Management Group LLC acquired a new stake in Recursion Pharmaceuticals in the first quarter worth $55,000. Finally, Universal Beteiligungs und Servicegesellschaft mbH bought a new stake in shares of Recursion Pharmaceuticals in the 1st quarter valued at $57,000. 89.06% of the stock is owned by institutional investors.

Analysts Set New Price Targets

RXRX has been the topic of several recent analyst reports. Weiss Ratings reiterated a “sell (d-)” rating on shares of Recursion Pharmaceuticals in a report on Wednesday, October 8th. Needham & Company LLC restated a “buy” rating and set a $8.00 target price on shares of Recursion Pharmaceuticals in a report on Thursday, September 11th. Two analysts have rated the stock with a Buy rating, three have issued a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Hold” and an average price target of $7.25.

Insiders Place Their Bets

In other news, insider Najat Khan sold 36,599 shares of the stock in a transaction that occurred on Monday, August 18th. The stock was sold at an average price of $5.52, for a total value of $202,026.48. Following the completion of the sale, the insider owned 668,197 shares of the company’s stock, valued at approximately $3,688,447.44. This represents a 5.19% decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. 8.43% of the stock is currently owned by corporate insiders.

Recursion Pharmaceuticals Trading Down 1.4%

Shares of NASDAQ:RXRX opened at $5.44 on Tuesday. The company’s 50-day moving average price is $5.27 and its two-hundred day moving average price is $5.21. The company has a debt-to-equity ratio of 0.02, a current ratio of 3.58 and a quick ratio of 3.58. Recursion Pharmaceuticals, Inc. has a one year low of $3.79 and a one year high of $12.36. The stock has a market capitalization of $2.36 billion, a PE ratio of -3.06 and a beta of 0.91.

Recursion Pharmaceuticals (NASDAQ:RXRX) last released its earnings results on Tuesday, August 5th. The company reported ($0.41) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.35) by ($0.06). The company had revenue of $19.10 million during the quarter, compared to analyst estimates of $15.38 million. Recursion Pharmaceuticals had a negative net margin of 1,004.91% and a negative return on equity of 76.09%. Recursion Pharmaceuticals’s revenue was up 33.3% compared to the same quarter last year. During the same period in the prior year, the firm posted ($0.40) EPS. On average, equities analysts forecast that Recursion Pharmaceuticals, Inc. will post -1.57 EPS for the current fiscal year.

Recursion Pharmaceuticals Company Profile

Recursion Pharmaceuticals, Inc operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase 2 clinical trial to treat cerebral cavernous malformation; REC-2282, which is in Phase 2/3 clinical trial for the treatment of neurofibromatosis type 2; REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-3964, which is in Phase 1 clinical trial to treat Clostridioides difficile infection; and REC-4881, which is in Phase 2 clinical trial to treat AXIN1 or APC mutant cancers.